Medical information Clinical review pending

Cytogenetics

FISH Ewing Sarcoma EWS 22q12 EWSR1 Rearrangement Test

This test uses Fluorescence In Situ Hybridization (FISH) to detect specific genetic rearrangements (EWSR1 gene at 22q12) associated with Ewing Sarcoma, a type of cancer often found in children and young adults. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue. Please ensure the Chromosome & FISH analysis Requisition Form (Form 17) is completed and submitted with the sample.
Results: Results are typically available within 7-8 working days. Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required for this test. The sample is typically obtained via biopsy.

Test priceKSh 17,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH Ewing Sarcoma EWS 22q12 EWSR1 Rearrangement Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Suspicion of Ewing Sarcoma based on clinical presentation (e.g., bone pain, swelling).
✓Evaluation of tumors where Ewing Sarcoma is a differential diagnosis.
✓Confirmation of Ewing Sarcoma diagnosis.
✓Guiding treatment strategies based on genetic findings.
✓Patients presenting with symptoms suggestive of bone or soft tissue cancer.

In plain language

What this test helps you understand

This test is used to help diagnose Ewing Sarcoma by detecting a specific genetic rearrangement (EWSR1 gene rearrangement at 22q12) that is characteristic of this type of cancer. It aids in confirming the diagnosis and guiding treatment decisions.

The FISH Ewing Sarcoma EWS 22q12 EWSR1 Rearrangement Test is a specialized diagnostic tool used to identify genetic changes linked to Ewing Sarcoma. This cancer primarily affects bones and soft tissues, often occurring in children and young adults. The test uses a technique called Fluorescence In Situ Hybridization (FISH) to look for rearrangements in the EWSR1 gene on chromosome 22. Detecting this specific rearrangement is a key factor in diagnosing Ewing Sarcoma. Early and accurate diagnosis is crucial for effective treatment planning and improving patient outcomes. This test helps healthcare providers confirm the diagnosis and guide appropriate management strategies.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required for this test. The sample is typically obtained via biopsy.

SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue. Please ensure the Chromosome & FISH analysis Requisition Form (Form 17) is completed and submitted with the sample.

MethodologyFluorescence In Situ Hybridization (FISH). This technique uses fluorescent probes that bind to specific DNA sequences on chromosomes, allowing visualization of genetic rearrangements under a microscope.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically detects the EWSR1 rearrangement at 22q12. It may not detect other genetic alterations associated with Ewing Sarcoma or other types of cancer. A negative result does not completely rule out Ewing Sarcoma, and further clinical evaluation may be necessary. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Ewing Sarcoma is a type of cancer that occurs in bones or the soft tissue around bones, primarily affecting children and young adults.

This test detects a specific genetic rearrangement involving the EWSR1 gene on chromosome 22, which is commonly found in Ewing Sarcoma.

The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block, usually obtained from a biopsy of the suspected tumor.

Results are generally available within 7-8 working days, but this can vary. Confirm with the laboratory before booking.

A positive result indicates the presence of the EWSR1 rearrangement, supporting a diagnosis of Ewing Sarcoma. A negative result suggests this specific rearrangement is not present. Discuss results with your doctor.

Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp